These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 22746355

  • 1. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
    Schmauss M, Jukić V, Siracusano A, Bidzan L, Badescu GM, Maciulis V, Lahaye M, Hoeben D, Tessier C, Schreiner A.
    Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
    [Abstract] [Full Text] [Related]

  • 2. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [Abstract] [Full Text] [Related]

  • 4. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B.
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A.
    Biol Psychiatry; 2007 Dec 15; 62(12):1363-70. PubMed ID: 17601495
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
    Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D.
    Biol Psychiatry; 2011 Dec 15; 70(12):1179-87. PubMed ID: 21831359
    [Abstract] [Full Text] [Related]

  • 7. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 8. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S, Don L, Herceg M, Bidzan L, Blanc M, Siracusano A, Maciulis V, Lahaye M, Schreiner A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan 03; 48():207-12. PubMed ID: 24096139
    [Abstract] [Full Text] [Related]

  • 9. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS.
    Int Clin Psychopharmacol; 2012 Sep 03; 27(5):267-74. PubMed ID: 22809972
    [Abstract] [Full Text] [Related]

  • 10. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M.
    J Clin Psychopharmacol; 2007 Feb 03; 27(1):6-14. PubMed ID: 17224706
    [Abstract] [Full Text] [Related]

  • 11. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA, Bettinger TL, Argo TR.
    Clin Ther; 2008 Feb 03; 30(2):231-48. PubMed ID: 18343262
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J.
    Int Clin Psychopharmacol; 2008 Nov 03; 23(6):343-56. PubMed ID: 18854723
    [Abstract] [Full Text] [Related]

  • 13. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG, Wu JH, Mao L.
    Curr Med Res Opin; 2008 Jun 03; 24(6):1807-15. PubMed ID: 18559166
    [Abstract] [Full Text] [Related]

  • 14. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.
    J Psychopharmacol; 2011 May 03; 25(5):685-97. PubMed ID: 20615933
    [Abstract] [Full Text] [Related]

  • 15. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
    Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E, Louzã MR, Quevedo J, Elkis H, Zorzetto Filho D, Périco Cde A, Lawson FL, Appolinário JC.
    Curr Med Res Opin; 2014 Apr 03; 30(4):695-709. PubMed ID: 24289141
    [Abstract] [Full Text] [Related]

  • 16. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM.
    Int Clin Psychopharmacol; 2008 Jul 03; 23(4):209-15. PubMed ID: 18545059
    [Abstract] [Full Text] [Related]

  • 17. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM, Bossie CA, Turkoz I, Alphs L.
    Schizophr Res; 2009 Aug 03; 113(1):56-64. PubMed ID: 19560322
    [Abstract] [Full Text] [Related]

  • 18. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
    Kim EY, Chang SM, Shim JC, Joo EJ, Kim JJ, Kim YS, Ahn YM.
    Curr Med Res Opin; 2013 Oct 03; 29(10):1231-40. PubMed ID: 23777311
    [Abstract] [Full Text] [Related]

  • 19. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
    Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG.
    Int Clin Psychopharmacol; 2010 May 03; 25(3):155-64. PubMed ID: 20216424
    [Abstract] [Full Text] [Related]

  • 20. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM, Keating GM.
    Drugs; 2010 Jul 09; 70(10):1295-317. PubMed ID: 20568835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.